Pricing Log in Create free account
Friday 6 November 2026 Export ABCL’s income statement to Excel — free account

AbCellera Biologics Inc.

ABCL Healthcare Biotechnology

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.

Revenue
−76.3%
EPS
−50.0%
Free cash flow
+152.0%

Quarter to June 2026, against a year earlier

11.89 0.76 +6.83%
Market cap
$3.6B
P/E
0.0×
Fwd P/E
−18.4×
Dividend yield
—
F-score
5/9
Altman Z
1.66
Beneish M
−1.06
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

AbCellera Biologics Inc. (ABCL) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, AbCellera Biologics Inc. (ABCL) trades at a P/B ratio of 4.1×. Over the past ten years it has ranged from 0.6× (April 2025) to 1,288× (December 2020); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.1× 29.38%
FY2024 0.8× (43.21%)
FY2023 1.4× (34.45%)
FY2022 2.2× (42.94%)
FY2021 3.8× (50.16%)
FY2020 7.7× (99.40%)
FY2019 1,288× 0.00%
FY2018 1,288× —

Quarterly newest first

Period P/B ratio Change
Jun 2026 2.7× 137.43%
Mar 2026 1.1× 6.72%
Dec 2025 1.1× (32.25%)
Sep 2025 1.6× 53.38%
22 more quarters

Against its own ten years

Low 0.6× High 1,288×
Ten-year median 1.7×
Current reading's percentile 79

P/B ratio against peers

Company P/B ratio
PBLS Parabilis Medicines, Inc. compare 0.8×
ACAD ACADIA Pharmaceuticals Inc. compare 2.6×
XENE Xenon Pharmaceuticals Inc. compare 3.0×
TNGX Tango Therapeutics, Inc. compare 3.1×
ABCL AbCellera Biologics Inc. 3.8×
RLAY Relay Therapeutics, Inc. compare 3.9×
IOVA Iovance Biotherapeutics, Inc. compare 4.3×
EWTX Edgewise Therapeutics, Inc. compare 9.4×
ARQT Arcutis Biotherapeutics, Inc. compare 14.6×
Biotechnology industry median 2.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on ABCL